IPST started its contract research activities in 1999 by conducting hERG inhibition patch-clamp assays on transfected cell lines and freshly dispersed myocytes. IPST's services expanded to efficacy and cardiac safety studies, with vascular and cardiac muscle tension measurements and isolated organ models. Our in-vitro and ex-vivo assays are fully GLP-compliant. A new line of in-vivo pathology models was validated in 2010 to enhance IPST’s extensive range of efficacy services.